Axsome Therapeutics (NASDAQ:AXSM) Research Coverage Started at Wolfe Research

Wolfe Research initiated coverage on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report sent to investors on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $230.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $220.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, December 31st. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Wells Fargo & Company lifted their price target on shares of Axsome Therapeutics from $193.00 to $202.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $225.00 price objective on shares of Axsome Therapeutics in a research note on Monday. Finally, Leerink Partners raised their price target on Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. Seventeen research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $216.12.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $164.22 on Monday. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $191.50. The stock’s 50-day moving average is $175.23 and its two-hundred day moving average is $145.53. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.50. The firm has a market cap of $8.40 billion, a P/E ratio of -44.50, a PEG ratio of 36.15 and a beta of 0.40.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $196.00 million during the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics’s quarterly revenue was up 65.0% on a year-over-year basis. Analysts predict that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other news, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark E. Saad sold 37,577 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. This trade represents a 78.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 308,874 shares of company stock worth $51,390,805 over the last 90 days. Insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Axsome Therapeutics during the fourth quarter valued at approximately $2,844,000. Invesco Ltd. boosted its stake in Axsome Therapeutics by 28.6% in the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after buying an additional 282,937 shares in the last quarter. Strive Financial Group LLC acquired a new stake in Axsome Therapeutics in the 4th quarter valued at $62,000. Ameriflex Group Inc. bought a new stake in Axsome Therapeutics in the fourth quarter valued at $37,000. Finally, Mercer Global Advisors Inc. ADV grew its holdings in shares of Axsome Therapeutics by 64.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,222 shares of the company’s stock worth $588,000 after purchasing an additional 1,260 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” and $230 price target (about 40% upside), providing a fresh bullish catalyst and likely driving buy-side interest. Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation
• Positive Sentiment: Needham & Company also issued a Buy rating, adding to growing analyst bullishness that can support the share price if momentum continues. Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Needham & Company LLC
• Positive Sentiment: Axsome announced dosing the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness — a meaningful pipeline milestone that could drive long-term value if trials progress. Axsome Therapeutics Initiates CLARITY Phase 3 Trial…
• Positive Sentiment: Coverage noting Axsome’s stronger representation in Nasdaq index funds and related inflows may have supported upside pressure earlier in the session. Axsome (NASDAQ:AXSM) Reaches New Heights In The Nasdaq Index Fund
• Neutral Sentiment: Axsome will participate in multiple investor conferences in March (TD Cowen, etc.), which increases institutional visibility but is typically a neutral near-term event unless new guidance or data are released. Axsome Therapeutics to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Reported short-interest data in the feed is effectively zero/invalid for February (no meaningful days-to-cover), so it provides no clear explanatory signal for today’s move.
• Negative Sentiment: Q4 showed strong revenue growth (surge on Auvelity sales) but a wider-than-expected loss — a mixed earnings print that can prompt profit-taking despite top-line strength. Analysts and investors may be parsing margins, guidance and cash/burn assumptions after the report. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.